

REMARKS

Claims 82-115 are pending.

Formula (A) at page 6 of the specification, respectively, have been amended to correct the number of R⁶ groups. As described in the specification, three of the Qs may be a nitrogen atom. Therefore, the minimum number of R⁶ groups is 1 (when 3 Qs are nitrogen atoms) and the maximum number of R⁶ groups is 4 (when none of the Qs are nitrogen atoms). Formula (A) has been amended to correctly show 1-4 R⁶ groups. The bottom of page 7 and page 15 have been amended to correct a typographical error. As shown in formula (A), there are no R⁵ groups substituting the Qs in the ring. In addition, a revised Abstract has been submitted to make the corresponding change to formula (A).

Claim 82 has been amended to specify 2 R⁶ groups in formula (A) in view of the remarks above, i.e., because two Q are nitrogen atoms. The definition of Q has also been amended to reflect the changes made to the specification discussed above.

In addition, Claim 113 has been amended to specify a P2Y2 receptor agonist. That amendment is supported by the specification at page 20, line 10.

No new matter is believed to have been added to this application by the amendments submitted above.

Applicants submit that the present application is ready for examination on the merits. Early notice to this effect is earnestly solicited.


Respectfully submitted,

Customer Number

22850

Tel: (703) 413-3000
Fax: (703) 413 -2220
(OSMMN 06/04)

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. Oblon



James J. Kelly
Registration No. 41,504